A phase III trial evaluating the efficacy and tolerability of liposomal cisplatin [Lipoplatin] + gemcitabine versus conventional cisplatin + gemcitabine as first-line therapy in patients with advanced non-small cell lung cancer.

Trial Profile

A phase III trial evaluating the efficacy and tolerability of liposomal cisplatin [Lipoplatin] + gemcitabine versus conventional cisplatin + gemcitabine as first-line therapy in patients with advanced non-small cell lung cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2009

At a glance

  • Drugs Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2009 Interim results in 101 patients presented at ECCO/ESMO 2009.
    • 20 Jun 2007 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top